Intellia Therapeutics (NTLA) - CRISPR Specialist Impresses with Strong Pipeline!
Reading Time: 1 minute
Business Driver: Intellia Therapeutics (NTLA) specializes in the treatment of genetic diseases, primarily utilizing CRISPR-Cas9 technology. Among the most promising candidates in its product pipeline is Lonvoguran Ziclumeran, which is intended for the treatment of hereditary angioedema (HAE). After the successful completion of a Phase III clinical trial, the company plans to publish the study results in the first half of 2026, with a goal to apply for approval in the second half of 2026. Additionally, the company is testing Nexiguran Ziclumeran...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
